Sen. Kirsten Gillibrand (D-NY) tossed her hat in the 2020 presidential ring on Tuesday, announcing that she’s forming an exploratory committee.
The senator, who has an A grade from NORML, has become one of the most vocal advocates for federal marijuana reform in Congress, co-sponsoring multiple pieces of legislation and frequently talking about the issue in speeches and on social media. However, she did not start off her political career supporting cannabis reform.
Legislation And Policy Actions
Gillibrand did not co-sponsor any cannabis-related bills during her time in the House from 2007 to 2009, although colleagues filed several. Also during that period she voted against a floor amendment to protect state medical marijuana laws from federal interference.
However, she has evolved considerably on the issue in recent years and has signed her name onto several notable Senate cannabis bills. That includes the Marijuana Justice Act, which would remove cannabis from the Controlled Substances Act and punish states that enforce marijuana laws disproportionately against people of color.
She also co-sponsored legislation designed to protect medical marijuana states from federal interference, make it easier to conduct research on cannabis and legalize industrial hemp. Another research-related bill she co-sponsored would encourage the U.S. Department of Veterans Affairs to study how marijuana can treat specific conditions like post-traumatic stress disorder.
During testimony at a Senate Judiciary Sub-Committee hearing in 2016, Gillibrand said that “I know some people are saying that we should wait until there’s more research before changing the laws, but the one thing blocking the research is the law.”
In April 2018, Gillibrand sent a letter to then-Attorney General Jeff Sessions, requesting that he attend a meeting with some of her constituents who’ve been arrested for non-violent marijuana offenses.
“It is an American principle that, no matter the law, it should be applied equally to all people, regardless of their race or background,” she wrote. “Sadly, as you will hear from my constituents, for decades, the so-called ‘War on Drugs’ has not been pursued with equality.”
She also joined a bipartisan coalition of lawmakers who sent a letter to Sessions, imploring him to update them on the status of applications to cultivate cannabis for federal research purposes.
Quotes And Social Media Posts
For the last five years, Gillibrand has made Twitter a central platform for her marijuana reform advocacy.
Cannabis can treat a variety of illnesses, incl MS, cancer, epilepsy & seizures. Wrong for patients & doctors to fear prosecution.#CARERSAct
— Kirsten Gillibrand (@SenGillibrand) March 10, 2015
But while she initially focused on medical cannabis, her views on the issue evolved and so did the tweets on her feed.
DOJ should investigate how pharma helped create the opioid crisis, not institute policies that take marijuana based medicines from patients and needlessly target non-violent minority youths.
— Kirsten Gillibrand (@SenGillibrand) January 4, 2018
Gillibrand has routinely railed against the pharmaceutical industry, which she criticized for opposing cannabis legalization.
Big pharma keeps pushing back against legalizing medical marijuana because, in many cases, they want to continue to sell addictive drugs and dominate the market for drugs that address chronic pain. That's wrong.
It is time to rework our cannabis laws. https://t.co/g23trjnJcT
— Kirsten Gillibrand (@SenGillibrand) February 28, 2018
“To them, it’s competition for chronic pain, and that’s outrageous because we don’t have the crisis in people who take marijuana for chronic pain having overdose issues,” the senator said. “It’s not the same thing. It’s not as highly addictive as opioids are.”
She also criticized Sessions for rescinding Obama-era guidance that directed prosecutors to generally not interfere with state marijuana laws.
Attorney General Sessions' decision to restrict states’ ability to legalize and decriminalize marijuana is either willfully ignorant of the medical science or an act of greed on behalf of the pharmaceutical industry. In either case, it's an attack on patients, and it's wrong. pic.twitter.com/Kiw8nOmPb7
— Kirsten Gillibrand (@SenGillibrand) January 4, 2018
Black and Latino New Yorkers are almost 10 times more likely to be arrested for the possession of marijuana than their white neighbors – though usage rates are about the same.
— Kirsten Gillibrand (@SenGillibrand) April 22, 2018
“Millions of Americans’ lives have been devastated because of our broken marijuana policies, especially in communities of color and low-income communities,” Gillibrand said in a press release. “Just one minor possession conviction could take away a lifetime of opportunities for jobs, education, and housing, tear families apart, and make people more vulnerable to serving time in jail or prison down the road.”
“The reality that my 14-year-old son would likely be treated very differently from one of his Black or Latino peers if he was caught with marijuana is shameful. Legalizing marijuana is a social justice issue and a moral issue that Congress needs to address to help fix decades of injustice caused by our nation’s failed drug policies.”
The Marijuana Justice Act takes steps to fix stark inequalities in our criminal justice system and protects patients who need medication. It’s a commonsense bill – and I’m proud to join @CoryBooker as a cosponsor. Americans have spoken and demanded change. It’s time to act. pic.twitter.com/1VfFbEipYJ
— Kirsten Gillibrand (@SenGillibrand) March 3, 2018
Gillibrand’s 2018 Senate reelection campaign used a marijuana petition as a list-building technique.
“Discriminatory drug policies are robbing people and families of job opportunities, time with their loved ones and their futures. In New York, black and Latino people are almost 10 times more likely to be arrested for possession of marijuana than their white neighbors – though usage rates are the same,” the sign-up page said. “We have to act now to fix this horrible injustice. It’s time to decriminalize and legalize marijuana so we can begin repairing the harm caused by the failed War on Drugs. Add your name right now to tell Congress: Decriminalize marijuana!”
Beyond Capitol Hill, the senator has worked to build support for legislation to legalize marijuana in her home state of New York. He office has issued numerous press releases about cannabis policy in recent years.
During a presidential campaign stop in Iowa, she answered a question about how she would help military veterans by saying it is important to “make sure they have access to medicines like medical marijuana.”
Gillibrand’s campaign website also discusses her support for reform, under the headline, “We need to fix our broken criminal justice system.”
“When low-income people and people of color face huge disparities in arrests, sentencing and incarceration compared to wealthy and white people for the same or lesser charges, it’s a clear and urgent sign that we need to rectify the injustices in our criminal justice system,” it says. “We have a mass incarceration crisis, and institutional racism pervades the way we enforce laws. To rectify this, we should legalize marijuana at the federal level and expunge past records; reform our sentencing laws so that judges can have more flexibility when dealing with low-level, nonviolent drug offenses; change federal rules for our prisons; end cash bail; and invest resources in communities harmed by the racist war on drugs.”
Personal Experience With Marijuana
Gillibrand doesn’t appear to have publicly discussed whether she has ever consumed marijuana, but she has repeatedly cited conversations with families and patients who’ve benefited from medical cannabis as a motivating factor behind her reform advocacy.
Marijuana Under A Gillibrand Presidency
It stands to reason that the senator would prioritize federal marijuana reform as president, especially in light of her co-sponsorship of the Marijuana Justice Act and the extent to which she has focused on the issue in public statements. It seems likely that she would continue that record if elected to the Oval Office.
Photo element courtesy of Gillibrand 2010.
Three Major Cannabis Reform Bills Are Heading To The Texas House Floor
A Texas House committee unanimously approved a bill on Wednesday to expand the state’s medical marijuana program by adding over a dozen health conditions that would qualify patients for participation. And additional cannabis-related legislation is on the horizon, too, with lawmakers in position to potentially vote on marijuana decriminalization and hemp legalization in short order.
Under the medical marijuana bill, patients with cancer, autism, post-traumatic stress disorder, Alzheimer’s, Parkinson’s, Huntington’s disease, amyotrophic lateral sclerosis, Tourette syndrome, Crohn’s, ulcerative colitis, muscular dystrophy and multiple sclerosis would qualify to access cannabis. Patients who experience certain side effects such as severe nausea from conventional therapies would also be able to get medical cannabis.
That would mark a significant expansion of the state’s currently limited medical marijuana system, which only allows patients with intractable epilepsy who’ve exhausted their pharmaceutical options to access cannabis. Finding a specialist doctor to make the recommendation has been another challenge, which further explains why the program has roughly 600 registered medical marijuana patients in a state of about 29 million people.
“Overall, we’re really pleased to see unanimous support for the legislation out of the public health committee,” Heather Fazio, director of Texans for Responsible Marijuana Policy, told Marijuana Moment. “Legislators are taking this issue more seriously now than every before, and they’re responding to their constituents who want to see these laws changed.”
Fazio said she was especially encouraged that the legislation, which currently has more than 50 authors and coauthors, would establish an in-state research panel to study medical cannabis.
All that said, reform advocates aren’t entirely satisfied with the bill as it was amended. While the expansion would be a welcome development, lawmakers scaled back the proposal so that the 0.5 percent THC cap for medical cannabis products under current law would remain in place, whereas the original bill would have lifted it.
Additionally, there are concerns about certain terminology in the bill. Advocates hoped lawmakers would use the word “recommend” instead of “prescribe” when it comes to the doctor’s role in the program because “prescribing” marijuana could jeopardize health professionals given federal restrictions. That said, the legislation does define “prescription” in a way that offers some protections at the state level.
The bill now heads to the House Calendars Committee, where it will await placement on the agenda for a full House floor vote.
Texas might not seem like the most obvious destination for cannabis reform, but state lawmakers have become increasingly interested in tapping into the issue. Earlier this month, three House committees discussed a total of 11 cannabis-related bills—from decriminalizing marijuana to regulating hemp—in a single day.
A decriminalization bill advanced out of the House Criminal Jurisprudence Committee in a 5-2 vote last month. It’s possible that that legislation, which currently sits in the Calendars Committee, could receive a full House floor vote as early as next week. However, lawmakers are looking at multiple decriminalization bills that have been introduced this session and may decide to advance a different version.
Meanwhile, another cannabis bill is already scheduled to be debated in the full House next week. The legislation, introduced by Rep. Tracy King (D), would legalize hemp and its derivatives like CBD. The House Agriculture and Livestock Committee voted unanimously to advance the legislation earlier this month.
New: State Rep. Tracy King's bill which which would establish a hemp growing program in Texas and legalize hemp and hemp-derived products that contain <0.3% THC will get debated Tuesday in the House. #txlege
— Alexandra Samuels (@AlexSamuelsx5) April 18, 2019
“We’re seeing that policymakers are finally catching up with public opinion and where their constituents stand on this important issue that has affected so many live and families and communities over the last nearly a century,” Fazio said. “Thankfully people are having meaningful conversations about how current policies are failing and new ways that we can move forward. ”
Photo courtesy of Mike Latimer.
People Could Use Marijuana In Public Housing Under New Congressional Bill
People living in federally assisted housing would be allowed to use marijuana in compliance with state law under a bill introduced by Rep. Eleanor Holmes Norton (D-DC) on Thursday.
Current law prohibits those who use a federally illicit substance from being admitted into public housing, and landlords are able to evict such individuals. The congresswoman’s legislation is designed to protect people living in public housing or Section 8 housing from being displaced for using cannabis in states that have legalized for medical or adult use.
“Individuals living in federally funded housing should not fear eviction simply for treating their medical conditions or for seeking a substance legal in their state,” Norton said in a press release. “Increasingly, Americans are changing their views on marijuana, state by state, and it is time that Congress caught up with its own constituents.”
“With so many states improving their laws, this issue should have broad bipartisan appeal because it protects states’ rights,” she said.
The bill would also require the head of the Department of Housing and Urban Development (HUD) to enact regulations to restrict smoking marijuana at these facilities in the same way that it does for tobacco.
Norton introduced an earlier version of the Marijuana in Federally Assisted Housing Parity Act last year, but it did not receive a hearing or vote.
At least one HUD official, who oversees New York and New Jersey, has signaled an interest in amending federal law so that people who use cannabis retain the ability to live in federally assisted housing. Regional officer Lynne Patton tweeted last year that “[s]tate & federal law needs to catch up with medicinal marijuana usage & require private landlords to legally permit the same. Period.”
Photo courtesy of WeedPornDaily.
Hundreds Of People Are Sending CBD Comments To The FDA
The Food and Drug Administration (FDA) announced earlier this month that it was accepting public comments on CBD regulations, and more than 400 people have already made their voices heard.
Comments published on Regulations.gov range widely in subject matter, but the main theme running through them is that regulations should be light and companies should be able to lawfully market products containing cannabidiol. Many added that marijuana in general should be legalized, even though the agency did not request that people weigh in on that broader issue.
The comment period was designed to help inform an upcoming public hearing on CBD regulations that the FDA is holding on May 31. Amy Abernethy, principal deputy commission of the FDA, tweeted a link for stakeholders to register for the hearing on Wednesday.
Are there particular safety concerns re: products with cannabis/cannabis-derived compounds? How does the mode of delivery (e.g., ingestion, absorption, inhalation) affect the safety & exposure? Comments/data on important issues like these can help inform FDA reg. oversight.
— Dr. Amy Abernethy (@DrAbernethyFDA) April 17, 2019
We’re seeking input re: FDA’s reg. strategy for existing products, lawful pathways by which appropriate products containing cannabis/cannabis-derived compounds can be marketed & how to make them more predictable/efficient. Register or submit to the docket: https://t.co/xISRzDgN1S pic.twitter.com/maBllYjr3O
— Dr. Amy Abernethy (@DrAbernethyFDA) April 17, 2019
The FDA listed out several questions mostly concerning the safety of cannabis-derived products, how to enact quality control measures and what “validated analytical testing is needed” to ensure that CBD is manufactured in a consistent manner.
David Mangone, director of government affairs at Americans for Safe Access, offered some tips on how to submit effective comments in an earlier interview with Marijuana Moment, and one of the takeaways was that the FDA is primarily interested in receiving scientific evidence that addresses the agency’s specific questions—as opposed to personal anecdotes about CBD use.
Some, like Matthew Lubeck, followed that advice. He commented that CBD should be allowed into the food supply because “the bioavailability and reactiveness within the human body and the cannabinoid system” isn’t ideal when the compound is isolated.
Brent King offered an assessment examining the potential use of CBD as an exit drug from addictive substances such as opioids. He cited a study that showed reduced opioid overdoses in states that have loosened marijuana laws as an example.
“The gateway theory falls victim to the mistaken assumption that correlation alone implies causation,” King said. “Using the same logic, one could argue that drinking milk is a gateway to illicit drug use since most people who use illicit drugs also drank milk as young people.”
Others raised questions about the CBD market as it exists today—unregulated by the FDA as the agency continues to weigh possible options to allow hemp-derived CBD into the food supply or as dietary supplements. An anonymous comment expressed concerns about product consistency across companies that are already selling CBD, arguing that “variance from product to product is confusing” and makes it difficult to “make an informed decisions” about what products to use.
“The public needs protection from unscrupulous companies goals to get rich,” the person wrote.
All that said, most comments did not adhere to Mangone’s or the FDA’s guidelines. The vast majority of comments were anecdotal and individualized. People suffering from conditions such as anxiety, pain, post-traumatic stress disorder and insomnia urged the FDA to loosen restrictions on CBD, describing their own life-changing experience with the product. Several others talked about the health benefits of CBD that they observed in pets.
While that might not be what the agency asked for, that doesn’t change the fact that there is a broad consensus among those who took the time to comment: CBD is safe and has proven medical value, and people should be allowed to freely access it.
It’s not that simple from the FDA’s perspective, however. Former Commissioner Scott Gottlieb has repeatedly stressed that because CBD exists as an FDA-approved drug (Epidiolex) and hasn’t previously been introduced to the food supply, there’s no clear regulatory framework to put it through, even if that was the intention of the 2018 Farm Bill that legalized hemp and its derivatives.
Gottlieb has told members of Congress that additional legislation may be required to provide for the marketing of CBD, or else it may take years before the FDA can identify an alternative regulatory pathway. In the meantime, the FDA is taking a “risk-based” approach to enforcing laws governing CBD marketing that involves cracking down on companies making unsanctioned claims about the health benefits of their CBD products.
Federal requests for public input on cannabis-related policies are nothing new. Thousands offered their perspective on marijuana scheduling under international treaties when the FDA requested feedback on that issue last year. More recently, another federal agency solicited studies from the public on how cannabis can treat symptoms of Alzheimer’s disease.
Photo courtesy of Rick Proctor.